Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QRxPharma has announced the initial encouraging Phase III efficacy results for Q8003IR, an immediate release dual-opioid product intended for the acute management of moderate to severe pain.
Subscribe to our email newsletter
The double-blind, placebo-controlled study was designed to compare the efficacy and safety of four different dosage regimens of Q8003IR, a fixed ratio morphine/oxycodone combination.
Among all patients receiving Q8003IR, approximately 50% reported good to excellent global improvement (versus 13% for placebo) and demonstrated a strong dose-response effect (p<0.001) in reducing pain intensity scores [that is the sum of pain intensity difference over 48 hours relative to the first dose (SPID48)] and other measures of analgesic effect. Per treatment group, median doses received every four hours ranged from 3mg/2mg to 9mg/6mg of morphine/oxycodone. The data further demonstrate that Q8003IR was generally well tolerated, with a low rate of patient withdrawal (2% to 12% depending on dose versus 2% for placebo). In addition, there was minimal somnolence (2% to 8%) and changes to respiratory parameters (respiration rate, oxygen saturation) with no incidences of euphoria reported.